safety of glp-1 receptor agonists Comparative efficacy and for weight reduction: A model-based meta-analysis of placebo-controlled trials GLP1 receptor agonists are supported

However, the competitive landscape is rapidly evolving with next-generation molecules demonstrating superior efficacy

Age-associated cholesterol reduction triggers brain insulin resistance by facilitating ligand-independent receptor activation and pathway desensitization

doi: 10.1186/S44158-025-00237-Y 107 SherwinMHamburgerJKatzDDeMariaS

GLP-1 has a plasma half-life of only 1.5-3 min with a high clearance indicating degradation in blood (52, 72)

doi: 10.1111/dom.15896 78 HuangYNLiaoWLHuangJYLinYJYangSFHuangCCet al

527 Conclusions and perspective Primarily recognized for their role in diabetes mellitus treatment, GLP-1RAs have demonstrated significant benefits in cardiovascular health, skeletal muscle-related diseases, obesity management, and neurodegenerative conditions, among others